Introduction
Mature circulating erythrocytes enjoy an average life span of >100 days, which is eventually limited by senescence 1 . Prior to that, erythrocytes may be removed by suicidal death or eryptosis, which is characterized by erythrocyte shrinkage and breakdown of the cell membrane asymmetry with translocation of phosphatidylserine from the cell interior to the cell membrane surface. [1] [2] [3] [4] [5] [6] [7] [8] Eryptotic erythrocytes are rapidly cleared from circulating blood, 1, 9 as phosphatidylserine exposing erythrocytes bind to respective receptors of phagocytes, are engulfed and are subsequently degraded. 1 As soon as the loss of erythrocytes by stimulated eryptosis is not outweighed by parallel stimulation of erythropoiesis, anemia develops. 1 Phosphatidylserine at the surface of eryptotic erythrocytes further binds to endothelial cells, in large part, by interaction of phosphatidylserine with the CXC-Motiv-Chemokin 16/ Scavenger receptor (CXCL16/SRPSOX). 1 The adherence of erythrocytes to the vascular wall compromises microcirculation. 1 Moreover, phosphatidylserine exposing eryptotic erythrocytes bind to blood platelets and may thus trigger blood clotting and thrombosis. 1 Enhanced eryptosis is observed in several clinical conditions (Table 1) . Moreover, eryptosis is enhanced in the elderly. [34] [35] [36] Susceptibility to eryptosis increases with erythrocyte age 37 and the percentage of eryptotic erythrocytes increases following storage of blood. [38] [39] [40] [41] Erythrocytes from newborns are highly sensitive to oxidative stress leading to rapid eryptosis and subsequent clearance of those erythrocytes following birth.
energy depletion, oxidative stress, cellular K 1 loss, hyperthermia and a wide variety of xenobiotics 32, 36, including diverse cytostatic drugs (see below).
Anemia is common in malignancy. [77] [78] [79] [80] [81] [82] [83] [84] [85] The anemia is compounded by chemotherapy. 78, 79, [86] [87] [88] [89] Attempts to treat the anemia of malignancy by erythropoiesis-stimulating agents were associated with reduced patient survival time presumably because of stimulation of tumour growth and thrombosis. 79, [84] [85] [86] The present brief review discusses the compelling evidence that anemia of malignancy and chemotherapy results from stimulation of eryptosis, and may be avoided by xenobiotics counteracting eryptosis. The discussion is preceded by a description of the known signaling pathways orchestrating eryptosis. Owing to limitation of space, reviews had to be cited at several places instead of earlier original papers.
Cellular Mechanisms Orchestrating Eryptosis
Eryptosis is orchestrated by several signalling pathways. 5 Hyperosmotic shock activates a phospholipase A 2 with subsequent release of platelet-activating factor (PAF), which in turn stimulates ceramide formation by activation of a sphingomyelinase. 91 The signalling may further involve the heterotrimeric G-protein subunit Gai2. 92 Some triggers of eryptosis are effective through stimulation of caspases, 1 such as oxidative stress, leukotrienes and a-lipoic acid. 1, 93 Eryptosis is stimulated following genetic knockout of adenosine 5 0 -monophosphate deaminase (AMPD3) 94 and is influenced by regulatory small noncoding RNAs (ncRNAs). 95 Several kinases participate in the regulation of eryptosis. Pharmacological inhibition of protein kinase C or cyclindependent kinase 4 (CDK4) is followed by blunting of the eryptosis following excessive erythrocyte shrinkage and oxidative stress. 1, 96 Exposure of erythrocytes to hyperosmotic shock activates the p38 mitogen-activated kinase, which contributes to the stimulation of eryptosis. 1 Full stimulation of eryptosis by oxidative stress or energy depletion further requires casein kinase 1a (CK1a). Energy depletion in addition activates Janus-activated kinase JAK3, which in turn triggers eryptosis. 97 Energy depletion further stimulates the energy sensing AMP-activated kinase (AMPK), which inhibits eryptosis.
1 AMPK up-regulates p21-activated kinase 2 (PAK2) which similarly inhibits eryptosis. 1 Eryptosis is further inhibited by mitogen-and stress-activated kinase MSK1/2.
98
Stimulation of eryptosis by sorafenib and sunitinib points to inhibition of eryptosis by tyrosine kinases. Eryptosis is further inhibited by the cGMP-dependent protein kinase (cGKI). The cGKI is stimulated by nitric oxide (NO), which is accumulated in erythrocytes. 1 Similar to cGK1 and NO, dibutyrylcGMP inhibits eryptosis. 1 
Enhanced Eryptosis in Malignancy
Enhanced eryptosis has been described in lung cancer 99 and in myelodysplastic syndrome 2 and in mice with intestinal tumours because of adenomatous polyposis coli deficiency. 100 As shown in lung cancer patients, the hemoglobin concentration and packed cell volume were significantly lower than in healthy controls. 99 The anaemia prevailed in the patients despite a twofold increase in reticulocyte number in patients as in controls, an observation pointing to enhanced erythrocyte formation. 99 The percentage of phosphatidylserineexposing erythrocytes was twice as high in lung cancer patients as in healthy individuals. Without compensatory increase of erythropoiesis, the erythrocyte count and hemoglobin concentration would thus decrease to half. The eryptosis in malignancy is stimulated, at least in part, by a plasma component. The percentage of eryptotic erythrocytes was significantly higher following exposure of healthy 
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erythrocytes to plasma from patients with lung cancer than to plasma from healthy individuals. 99 Mechanisms involved in the triggering of eryptosis by lung cancer include oxidative stress and ceramide abundance. 99 Somewhat surprisingly, eryptosis in lung cancer patients was not paralleled by appreciable increase of cytosolic Ca 21 activity. 99 Stimulation of eryptosis in malignancy is presumably augmented by iron deficiency, a clinical condition common in patients with malignancy 101 and known to stimulate eryptosis. 1 Iron deficiency is associated with oxidative stress. The eryptosis in malignancy is compounded by cytostatic treatment. 99 Cytostatic drugs do not only trigger apoptosis of nucleated cells, but virtually all hitherto tested cytostatic drugs trigger eryptosis. 1 Cytostatic drugs shown to trigger eryptosis are listed in Table 2 . The drugs are effective by triggering Ca 21 entry, enhancing ceramide abundance, inducing oxidative stress and/or influencing kinase activities. 7 
Counteracting Eryptosis in Malignancy
Anemia in malignancy has been treated with erythropoiesis stimulating substances including erythropoietin, which, however, rather decrease the survival of patients presumably in part because of stimulation of tumor growth and thrombosis. 79, [84] [85] [86] Erythropoietin and related erythropoiesis stimulating substances could enhance tumor growth by inhibition of tumor cell apoptosis and by stimulation of angiogenesis. 139 At least in theory, thrombosis could result from an increase of phosphatidylserine exposing erythrocytes 1 . Untreated anemia is expected to stimulate the release of erythropoietin, 140, 141 which may similarly foster tumor growth, angiogenesis and thrombosis. In view of the enhanced percentage of suicidal erythrocytes in malignancy, the possibility should be considered that anemia could be prevented by inhibition of eryptosis. A wide variety of substances have previously been shown to inhibit eryptosis, as listed in Table 3 .
Inhibition of suicidal cell death may, however, in patients with malignancy, be similarly a double-edged sword, as simultaneous inhibition of cancer cell suicidal death would foster tumor growth. In view of this danger, substances are of particular interest, which stimulate apoptosis of tumor cells and by the same token inhibit eryptosis. Those dual effects are triggered for instance by teriflunomide, 144 which may thus prove useful in the treatment of anemia in patients with malignancy.
Conclusions
Anemia is prevalent in a wide range of malignancies and is an important side effect of chemotherapy. While different mechanisms have been implicated in the development of anemia in cancers and their chemotherapy, there is growing new evidence suggesting that eryptosis may contribute to the erythrocyte deficiency in cancer patients. A large number of eryptosis inhibitors have been identified which may, in theory, be used to counteract anemia in patients with malignancy. However, many of those substances simultaneously foster survival of tumor cells and may thus be rather harmful. Nevertheless, substances have been identified which stimulate apoptosis of tumor cells and by the same token inhibit eryptosis. Those substances may be particularly useful for the treatment of anemia in malignancy. We are not aware of any clinical study aiming at the prevention of eryptosis in anemia but do hope that this review will stimulate further research on (patho)physiology and pharmacology of eryptosis in anemic conditions and its translation into respective clinical trials. 
